{
  "eval_id": "S48",
  "eval_file": "evals/single/S48.json",
  "timestamp": "2025-09-18T16:55:17.041079Z",
  "model": "gpt-4.1",
  "temperature": 0.6,
  "rep_input": "Patient HR+/HER2- progressed after CDK4/6; what key label-based caveats should I discuss?",
  "model_output": "After progression on CDK4/6 in HR+/HER2- disease, label-based choices depend on prior endocrine agents, performance status, and presence of visceral disease. Please clarify these points so I can highlight the most relevant on-label considerations."
}